Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers A > Headlines for Angiotech Pharmaceuticals, Inc. > News item |
Angiotech maintained by Merrill at buy
Angiotech Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a buy rating with a price target on the stock of $20 per share following second-quarter results. Angiotech shares in the United States on Friday were down $0.11, or 0.80%, at $13.69 on volume of 1,141,309 shares versus the three-month running average of 557,674 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.